The PR61 program (LNP expressing cell-permeable PTEN) is progressing toward clinical trials.
The PR93 program (LNP expressing cell-permeable PTEN) is progressing toward animal proof-of-concept.
For collaboration and partnering opportunities please contact us at: therapten@gmail.com.